Drug Safety

, Volume 38, Issue 1, pp 33–54 | Cite as

The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases

  • Hazel Mae A. Abraham
  • C. Michael White
  • William B. White
Review Article


All national guidelines for the management of hypertension recommend angiotensin receptor blockers (ARBs) as an initial or add-on antihypertensive therapy. The eight available ARBs have variable clinical efficacy when used for control of hypertension. Additive blood pressure-lowering effects have been demonstrated when ARBs are combined with thiazide diuretics or dihydropyridine calcium channel blockers, augmenting hypertension control. Furthermore, therapeutic use of ARBs goes beyond their antihypertensive effects, with evidence-based benefits in heart failure and diabetic renal disease particularly among angiotensin-converting enzyme inhibitor-intolerant patients. On the other hand, combining renin–angiotensin system blocking agents, a formerly common practice among medical subspecialists focusing on the management of hypertension, has ceased, as there is not only no evidence of cardiovascular benefit but also modest evidence of harm, particularly with regard to renal dysfunction. ARBs are very well tolerated as monotherapy, as well as in combination with other antihypertensive medications, which improve adherence to therapy and have become a mainstay in the treatment of stage 1 and stage 2 hypertension.


Losartan Amlodipine Valsartan Triple Therapy Candesartan 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Funding and conflicts of interest

No sources of funding were used in the preparation of this study. Hazel Mae A. Abraham, C. Michael White and William B. White have no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Data from the National Health and Nutrition Examination Survey (NHANES). National Center for Health Statistics. Health, United States, 2013: with special feature on prescription drugs. Hyattsville. 2014. http://www.cdc.gov/nchs/data/hus/hus13.pdf#064. Accessed 19 July 2014.
  2. 2.
    Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560–72.PubMedGoogle Scholar
  3. 3.
    James PA, Oparil S, Carter BL, et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.PubMedGoogle Scholar
  4. 4.
    White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16:14–26.Google Scholar
  5. 5.
    Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. Eur Heart J. 2013;34:2159–219.PubMedGoogle Scholar
  6. 6.
    Dasgupta K, Quinn RR, Zarnke KB, et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2014;30:485–501.PubMedGoogle Scholar
  7. 7.
    American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care. 2013;36(Suppl 1):s11–66.PubMedCentralGoogle Scholar
  8. 8.
    Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11:627–36.PubMedCentralPubMedGoogle Scholar
  9. 9.
    Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011;12:65–82.PubMedGoogle Scholar
  10. 10.
    Pasternak B, Svanström H, Callréus T, Melbye M, Hviid A. Use of angiotensin receptor blockers and the risk of cancer. Circulation. 2011;123:1729–36.Google Scholar
  11. 11.
    Brenner GM, Pharmacology Stevens CW, Edition Fourth. Philadelphia. Pennsylvania: Saunders; 2013.Google Scholar
  12. 12.
    Appel GB, Appel AS. Angiotensin II receptor antagonists: role in hypertension, cardiovascular disease, and renoprotection. Prog Cardiovasc Dis. 2004;47:105–15.PubMedGoogle Scholar
  13. 13.
    Weir MR, Dzau VJ. The renin–angiotensin–aldosterone system: a specific target for hypertension management. Am J Hypertens. 1999;12(12 Pt 3):205S–13S.PubMedGoogle Scholar
  14. 14.
    Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens. 2000;14(Suppl 1):S73–86.PubMedGoogle Scholar
  15. 15.
    Brunner HR. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am J Cardiol. 2001;87(8A):3C–9C.PubMedGoogle Scholar
  16. 16.
    Alderman MH, Madhavan S, Ooi WL, et al. Association of the renin–sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324:1098–104.PubMedGoogle Scholar
  17. 17.
    Burnier M. Angiotensin II, type 1 receptor blockers. Circulation. 2001;103:904–12.PubMedGoogle Scholar
  18. 18.
    Lauer D, Slavic S, Sommerfeld M, et al. Angiotensin type 2 receptor stimulation ameliorates left ventricular fibrosis and dysfunction via regulation of tissue inhibitor of matrix metalloproteinase 1/matrix metalloproteinase 9 axis and transforming growth factor β1 in the rat heart. Hypertension. 2014;63:e60–7.PubMedGoogle Scholar
  19. 19.
    McClellan KJ, Balfour JA. Eprosartan. Drugs 1998;55:713–720.Google Scholar
  20. 20.
    Miura S, Karnik SS, Saku K. Review: Angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst. 2011;12:1–7.PubMedCentralPubMedGoogle Scholar
  21. 21.
    White WB, Weber MA, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011;57:413–20.PubMedGoogle Scholar
  22. 22.
    Cozaar: prescribing information. Updated 2013. Merck Sharp & Dohme Corp., Whitehouse Station. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020386s060lbl.pdf. Accessed 1 June 2014.
  23. 23.
    Diovan: prescribing information. Updated 2014. Novartis Pharmaceuticals Corp., East Hanover. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020665s034s035lbl.pdf. Accessed 1 June 2014.
  24. 24.
    Atacand: prescribing information. Updated 2013. Takeda Pharmaceutical Company, Wilmington. http://www1.astrazeneca-us.com/pi/Atacand.pdf. Accessed 1 June 2014.
  25. 25.
    Avapro: prescribing information. Updated 2014. Sanofi-Aventis, Bridgewater. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020757s064lbl.pdf. Accessed 1 June 2014.
  26. 26.
    Benicar: prescribing information. Updated 2014. Daiichi Sankyo, Parsippany. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021286s031lbl.pdf. Accessed 1 June 2014.
  27. 27.
    Micardis: prescribing information. Updated 2012. Boehringer Ingelheim, Ridgefield. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020850s033lbl.pdf. Accessed 1 June 2014.
  28. 28.
    Teveten: prescribing information. Updated 2011. Abbott Laboratories, North Chicago. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020738s026lbl.pdf. Accessed 1 June 2014.
  29. 29.
    Edarbi: prescribing information. Updated 2011. Takeda Pharmaceutical Company, Deerfield. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/200796s000lbl.pdf. Accessed 1 June 2014.
  30. 30.
    Song JC, White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy. 2000;20:130–9.PubMedGoogle Scholar
  31. 31.
    Hübner R, Högemann AM, Sunzel M, et al. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens. 1997;11(Suppl 2):S19–25.PubMedGoogle Scholar
  32. 32.
    Scott LJ, McCormack PL. Olmesartan medoxomil a review of its use in the management of hypertension. Drugs. 2008;68:1239–72.PubMedGoogle Scholar
  33. 33.
    Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res. 2004;27:457–64.PubMedGoogle Scholar
  34. 34.
    Brunner HR. The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. Am J Hypertens. 1997;10:311S–7S.PubMedGoogle Scholar
  35. 35.
    Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs. 2001;61:1501–29.PubMedGoogle Scholar
  36. 36.
    Chang C, Bahadduri PM, et al. Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos. 2006;34:1976–84.PubMedGoogle Scholar
  37. 37.
    Black HR, Bailey J, Zappe D, Samuel R. Valsartan: more than a decade of experience. Drugs. 2009;69:2393–414.PubMedGoogle Scholar
  38. 38.
    Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press. 1998;7:53–9.PubMedGoogle Scholar
  39. 39.
    Lacourcière Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan Study Investigators. Am J Hypertens. 1999;12:1181–7.PubMedGoogle Scholar
  40. 40.
    Gradman AH, Lewin A, Bowling BT, et al. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group. Heart Dis. 1999;1:52–7.PubMedGoogle Scholar
  41. 41.
    Manolis AJ, Grossman E, Jelakovic B, et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Clin Ther. 2000;22:1186–203.PubMedGoogle Scholar
  42. 42.
    Vidt DG, White WB, Ridley E, et al. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II. J Hum Hypertens. 2001;15:475–80.PubMedGoogle Scholar
  43. 43.
    Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest. 2003;23:419–30.Google Scholar
  44. 44.
    Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich). 2001;3(283–91):318.Google Scholar
  45. 45.
    Giles TD, Oparil S, Silfani TN, Wang A, Walker JF. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich). 2007;9:187–95.Google Scholar
  46. 46.
    Lee YT, Lee CM, Lin CS et al. A double-blind comparison of the efficacy and tolerability of telmisartan 40–80 mg vs. losartan 50–100 mg in Taiwanese hypertensive patients. Int J Clin Pract (Suppl). 2004;145:40–5.Google Scholar
  47. 47.
    Mallion J, Siche J, Lacourcière Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens. 1999;13:657–64.PubMedGoogle Scholar
  48. 48.
    Zhu JR1, Bai J, Cai NS et al. Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study. Int J Clin Pract (Suppl). 2004;145:46–9.Google Scholar
  49. 49.
    Calvo C, Hermida RC, Ayala DE, Ruilope LM. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens. 2004;22:837–46.PubMedGoogle Scholar
  50. 50.
    White WB, Lacourcière Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens. 2004;17:347–53.PubMedGoogle Scholar
  51. 51.
    Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. Am J Hypertens. 1998;11:445–53.PubMedGoogle Scholar
  52. 52.
    Mancia G, Korlipara K, van Rossum P, Villa G, Silvert B. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit. 2002;7:135–42.PubMedGoogle Scholar
  53. 53.
    Sica D, White WB, Weber MA, et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2001;13:467–72.Google Scholar
  54. 54.
    Bakris G, Gradman A, CLAIM Study Investigators, et al. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens (Greenwich). 2001;3:16–21.Google Scholar
  55. 55.
    Littlejohn T, Mroczek W, Marbury T, VanderMaelen CP, Dubiel RF. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol. 2000;16:1123–32.PubMedGoogle Scholar
  56. 56.
    White WB, Anwar YA, Mansoor GA, Sica DA. Evaluation of the 24-hour blood pressure effects of eprosartan in patients with systemic hypertension. Am J Hypertens. 2001;14:1248–55.PubMedGoogle Scholar
  57. 57.
    Waeber B. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. Expert Rev Cardiovasc Ther. 2003;1:43–50.PubMedGoogle Scholar
  58. 58.
    Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. J Clin Hypertens (Greenwich). 2011;13:639–43.Google Scholar
  59. 59.
    Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2007;21:220–4.PubMedGoogle Scholar
  60. 60.
    Bönner G, Landers B, Bramlage P. Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T). Vasc Health Risk Manag. 2011;7:85–95.PubMedCentralPubMedGoogle Scholar
  61. 61.
    Sachse A, Verboom CN, Jäger B. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension. J Hum Hypertens. 2002;16:169–76.PubMedGoogle Scholar
  62. 62.
    Rosenbaum D, Girerd X. Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension. Curr Med Res Opin. 2012;28:179–86.PubMedGoogle Scholar
  63. 63.
    Saruta T, Ogihara T, Matsuoka H, et al. Antihypertensive efficacy and safety of fixed-dose combination therapy with losartan plus hydrochlorothiazide in Japanese patients with essential hypertension. Hypertens Res. 2007;30:729–39.PubMedGoogle Scholar
  64. 64.
    Salerno CM, Demopoulos L, Mukherjee R, Gradman AH. Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension. J Clin Hypertens (Greenwich). 2004;6:614–20.Google Scholar
  65. 65.
    Neutel JM, Franklin SS, Lapuerta P, et al. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens. 2008;22:266–74.PubMedGoogle Scholar
  66. 66.
    Calhoun DA, Glazer RD, Pettyjohn FS, et al. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension. Curr Med Res Opin. 2008;24:2303–11.PubMedGoogle Scholar
  67. 67.
    Lacourcière Y, Martin K. Comparison of a fixed-dose combination of 40 mg telmisartan plus 12.5 mg hydrochlorothiazide with 40 mg telmisartan in the control of mild to moderate hypertension. Am J Ther. 2002;9:111–7.PubMedGoogle Scholar
  68. 68.
    Lacourcière Y, Tytus R, O’Keefe D, et al. Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy. J Hum Hypertens. 2001;15:763–70.PubMedGoogle Scholar
  69. 69.
    Neldam S, Edwards C. Results of increasing doses of hydrochlorothiazide in combination with an angiotensin receptor blocker in patients with uncontrolled hypertension. J Clin Hypertens (Greenwich). 2008;10:612–8.Google Scholar
  70. 70.
    Sica D, Bakris GL, White WB, et al. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich). 2012;14:284–92.Google Scholar
  71. 71.
    Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30:587–604.PubMedGoogle Scholar
  72. 72.
    Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29:563–80.PubMedGoogle Scholar
  73. 73.
    Flack JM, Calhoun DA, Satlin L, et al. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens. 2009;23:479–89.PubMedGoogle Scholar
  74. 74.
    Neutel JM, Mancia G, Black HR, et al. Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study. J Clin Hypertens (Greenwich). 2012;14:206–15.Google Scholar
  75. 75.
    Hong BK, Park CG, Kim KS, et al. Comparison of the efficacy and safety of fixed-dose amlodipine/losartan and losartan in hypertensive patients inadequately controlled with losartan: a randomized, double-blind, multicenter study. Am J Cardiovasc Drugs. 2012;12:189–95.PubMedGoogle Scholar
  76. 76.
    Rakugi H, Ogihara T, Miyata Y, Sasai K, Totsuka N. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2012;34:838–48.PubMedGoogle Scholar
  77. 77.
    Calhoun DA, Lacourcière Y, Crikelair N, Jia Y, Glazer RD. Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension. Curr Med Res Opin. 2013;29:901–10.PubMedCentralPubMedGoogle Scholar
  78. 78.
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.Google Scholar
  79. 79.
    Calhoun DA, Lacourcière Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009;54:32–9.PubMedGoogle Scholar
  80. 80.
    Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32:1252–69.PubMedGoogle Scholar
  81. 81.
    Roth EM, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis. J Clin Hypertens (Greenwich). 2013;15:584–92.Google Scholar
  82. 82.
    Chrysant SG, Littlejohn T 3rd, Izzo JL Jr, et al. Triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study. Am J Cardiovasc Drugs. 2012;12:233–43.PubMedGoogle Scholar
  83. 83.
    Chrysant SG, Izzo JL Jr, Kereiakes DJ, Littlejohn T 3rd, Oparil S, et al. Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study. J Am Soc Hypertens. 2012;6:132–41.PubMedGoogle Scholar
  84. 84.
    Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin–angiotensin system: meta-analysis of randomised trials. BMJ. 2013;346:360.Google Scholar
  85. 85.
    Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–53.PubMedGoogle Scholar
  86. 86.
    Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204–13.PubMedGoogle Scholar
  87. 87.
    Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet. 2004;364:937–52.PubMedGoogle Scholar
  88. 88.
    Dahlöf B, Devereux RB, Kjeldsen SE, LIFE Study Group, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.PubMedGoogle Scholar
  89. 89.
    Julius S, Kjeldsen SE, Brunner H, et al. VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens. 2003;16:544–8.PubMedGoogle Scholar
  90. 90.
    Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875–86.PubMedGoogle Scholar
  91. 91.
    Yusuf S, Teo K, Anderson C, Pogue J, et al. Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174–83.PubMedGoogle Scholar
  92. 92.
    Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–8.PubMedGoogle Scholar
  93. 93.
    Viberti G, Wheeldon NM, Microalbuminuria Reduction with Valsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:672–8.PubMedGoogle Scholar
  94. 94.
    Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.PubMedGoogle Scholar
  95. 95.
    Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.PubMedGoogle Scholar
  96. 96.
    Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582–7.PubMedGoogle Scholar
  97. 97.
    Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–906.PubMedGoogle Scholar
  98. 98.
    Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752–60.PubMedGoogle Scholar
  99. 99.
    Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759–66.PubMedGoogle Scholar
  100. 100.
    Granger CB, McMurray JJ, Yusuf S, CHARM Investigators and Committees, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772–6.PubMedGoogle Scholar
  101. 101.
    McMurray JJ, Ostergren J, Swedberg K, CHARM Investigators and Committees, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767–71.PubMedGoogle Scholar
  102. 102.
    Yusuf S, Pfeffer MA, Swedberg K, CHARM Investigators and Committees, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet. 2003;362:777–81.Google Scholar
  103. 103.
    Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–75.PubMedGoogle Scholar
  104. 104.
    Massie BM, Carson PE, McMurray JJ, I-PRESERVE Investigators, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456–67.Google Scholar
  105. 105.
    Visser LE, Stricker BH, van der Velden J, Paes AH, Bakker A. Angiotensin converting enzyme inhibitor associated cough: a population-based case–control study. J Clin Epidemiol. 1995;48:851–7.PubMedGoogle Scholar
  106. 106.
    Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med. 1992;117:234–42.PubMedGoogle Scholar
  107. 107.
    Caldeira D, David C, Sampaio C. Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2012;12:263–77.PubMedGoogle Scholar
  108. 108.
    Rubio-Tapia A, Herman ML, Ludvigsson JF, et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc. 2012;87:732–8.PubMedCentralPubMedGoogle Scholar
  109. 109.
    FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM359496.pdf. Accessed 30 Sept 2014.
  110. 110.
    Greywoode R, Braunstein E, Arguelles-Grande C, et al. Olmesartan, other antihypertensives, and chronic diarrhea among patients undergoing endoscopic procedures: a case–control study. Mayo Clin Proc. 2014;89:1239–43.PubMedGoogle Scholar
  111. 111.
    Fujiwara W, Izawa H, Ukai G, et al. Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles. Heart Vessel. 2013;28:316–22.Google Scholar
  112. 112.
    Mengden T, Hübner R, Bramlage P. Office and ambulatory blood pressure control with a fixed-dose combination of candesartan and hydrochlorothiazide in previously uncontrolled hypertensive patients: results of CHILI CU Soon. Vasc Health Risk Manag. 2011;7:761–9.PubMedCentralPubMedGoogle Scholar
  113. 113.
    Fogari R, Taddei S, Holm-Bentzen M, et al. Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension. Clin Drug Invest. 2010;30:581–97.Google Scholar
  114. 114.
    Lapuerta P, Franklin S. The risks and benefits of initial irbesartan/hydrochlorothiazide combination therapy in patients with severe hypertension. J Clin Hypertens. 2009;11:277–83.Google Scholar
  115. 115.
    Pool JL, Glazer R, Weinberger M, et al. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther. 2007;29:61–73.PubMedGoogle Scholar
  116. 116.
    Weir M, Crikelair N, Levy D. Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension. J Clin Hypertens. 2007;9:103–12.Google Scholar
  117. 117.
    White WB, Calhoun D, Samuel R, et al. Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? The Valsartan Hydrochlorothiazide Diuretic for Initial Control and Titration to Achieve Optimal Therapeutic Effect (Val-DICTATE) trial. J Clin Hypertens (Greenwich). 2008;10:450–8.Google Scholar
  118. 118.
    Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB–MI paradox. Circulation. 2006;114:838–54.PubMedGoogle Scholar
  119. 119.
    Haller H, Ito S, Izzo JL Jr, Januszewicz A, ROADMAP Trial Investigators, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364:907–17.Google Scholar
  120. 120.
    Imai E, Chan JC, Ito S, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54:2978–86.PubMedCentralPubMedGoogle Scholar
  121. 121.
    FDA Drug Safety Communication. FDA review of cardiovascular risks for diabetics taking hypertension drug olmesartan not conclusive; label updates required. http://www.fda.gov/Drugs/DrugSafety/ucm402323.htm. Accessed 30 Sept 2014.
  122. 122.
    Cheung BM, Cheung GT, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. J Hum Hypertens. 2006;20:37–43.PubMedGoogle Scholar
  123. 123.
    Verdecchia P, Angeli F, Gattobigio R, Reboldi GP. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J. 2005;26:2381–6.PubMedGoogle Scholar
  124. 124.
    McDonald MA, Simpson SH, Ezekowitz JA, Gyenes G, Tsuyuki RT. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ. 2005;331:873.Google Scholar
  125. 125.
    Volpe M, Mancia G, Trimarco B. Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. J Hypertens. 2005;23:2113–8.PubMedGoogle Scholar
  126. 126.
    Bangalore S, Kumar S, Wetterslev J, Messerli FH. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ. 2011;342:d2234.PubMedCentralPubMedGoogle Scholar
  127. 127.
    Bhaskaran K, Douglas I, Evans S, van Staa T, Smeeth L. Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database. BMJ. 2012;344:e2697.PubMedCentralPubMedGoogle Scholar
  128. 128.
    Giles TD, Weber MA, Basile J, et al. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomized, multicenter study. Lancet. 2014;383:1889–98.PubMedGoogle Scholar
  129. 129.
    Yusuf S, Diener H, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225–37.PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Hazel Mae A. Abraham
    • 1
  • C. Michael White
    • 2
  • William B. White
    • 1
  1. 1.Division of Hypertension and Clinical Pharmacology, Calhoun Cardiology Center, University of Connecticut Health CenterUniversity of Connecticut School of MedicineFarmingtonUSA
  2. 2.University of Connecticut School of Pharmacy, Hartford HospitalStorrsUSA

Personalised recommendations